Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

54.78 +0.55 (+1.01%)
Streaming Delayed Price Updated: 1:09 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
News headline image
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health' ↗
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public... 
Via Benzinga
Topics Government
GSK Secures UK Approval For First New Oral Antibiotic In 30 Years To Treat Resistant Urinary Tract Infections ↗
Via Stocktwits
News headline image
Price Over Earnings Overview: GSK ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
What Does the Market Think About GSK? ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About GSK? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence ↗
Via Stocktwits
News headline image
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study ↗
Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025. 
Via Benzinga
News headline image
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans ↗
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth ↗
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets. 
Via Benzinga
News headline image
GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’ ↗
GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate. 
Via Stocktwits
Topics Artificial Intelligence World Trade
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact ↗
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion. 
Via Benzinga
News headline image
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data ↗
FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma. 
Via Benzinga
News headline image
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
From GSK plc
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning ↗
FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision. 
Via Benzinga
News headline image
Dow Futures Edge Higher As Strong Earnings Boost Investor Confidence: AXP, NFLX, IBKR, GSK Among Stocks To Watch ↗
While Dow Jones futures were up 0.07% at the time of writing, the S&P 500 futures were up 0.03%. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay Optimistic ↗
Despite the setback, GSK defended the drug’s potential, citing strong results from DREAMM trials. 
Via Stocktwits
News headline image
US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation
From GSK plc
Via Business Wire
News headline image
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults ↗
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
News headline image
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
News headline image
GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance ↗
A decision by the FDA on the new submission is expected in the first half of 2026. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.